YouTube2Text

4 Stocks to Buy Before the End of 2026! — Transcript

by The Motley Fool · 3,408 words · 509 segments · language en · Watch on YouTube

Full transcript

  1. 0:00Welcome back to the channel everyone.
  2. 0:01Today Neil and I are going to be talking
  3. 0:03about four stocks that we think look
  4. 0:05like great [music] buys before the end
  5. 0:07of 2026.
  6. 0:09Hard to believe that we're already
  7. 0:10getting down to the last couple months
  8. 0:12of [music] the year. There's a lot of
  9. 0:13businesses that I think we both have on
  10. 0:15our watch lists on our buy lists and
  11. 0:17we're going to be talking about some
  12. 0:18names across a few different industries
  13. 0:20right now. [music] A couple of these
  14. 0:21might be a little bit more unexpected.
  15. 0:23Excited to dive right in.
  16. 0:31Neil, good to see you today.
  17. 0:34>> Good to see you as well. And it is quite
  18. 0:36uh quite crazy that we are almost almost
  19. 0:40in 2027.
  20. 0:42So yeah, whoever is still uh wanted to
  21. 0:44sign up to the gym, something that you
  22. 0:47promised yourself in January may maybe
  23. 0:49January 2027,
  24. 0:51>> you have another chance. It's coming
  25. 0:52right around the corner.
  26. 0:54Uh but I'll I'll uh start off with my
  27. 0:58first one. My first one is a name that
  28. 1:00did report on Monday, November 9th,
  29. 1:04their quarterly figures, and that's
  30. 1:05Rocket Lab. Now, Rocket Lab is a company
  31. 1:08where I don't think looking at it from a
  32. 1:12purely valuation standpoint anybody's
  33. 1:14going to buy it because it's cheap. It's
  34. 1:16just less expensive. And it's also about
  35. 1:20what the company could look like 5 10
  36. 1:22years down the line. Now they reported
  37. 1:25revenue up 73% year-over-year, 14.4% up
  38. 1:30sequentially.
  39. 1:32They of course they launch rockets. They
  40. 1:34have a launch business and they also
  41. 1:36have a a space systems business. That
  42. 1:39one was up 13% uh sequentially which is
  43. 1:42and it was around I think 80% of the
  44. 1:44overall revenue. All of that is is good
  45. 1:47and fine, but the real story is again
  46. 1:49about what happens in the future. Rocket
  47. 1:53Lab stock, I think we reached a peak of
  48. 1:55$150 this year. It's now trading in the
  49. 1:57low $50. So quite quite a rocket crash
  50. 2:02uh since the uh since the highs. But the
  51. 2:06reason why this has happened is not
  52. 2:08because of a rocket exploded. No, it's
  53. 2:10because one was super expensive,
  54. 2:12overvalued, and two, their next big
  55. 2:16rocket, which is Neutron, was supposed
  56. 2:18to have its first flight, let's say, at
  57. 2:22the end of this year, although I don't
  58. 2:24think that was realistic, and that was
  59. 2:26delayed yet again. It's been quite a
  60. 2:30couple of quarters, maybe a year or two
  61. 2:32of delays. The thing here is nice for
  62. 2:352027. We still don't know when in 2027
  63. 2:38where it's going to be probably not Q1
  64. 2:40but maybe Q2 maybe midway 2027. And the
  65. 2:44reason why Neutron is so important is
  66. 2:46because well whenever you launch a a
  67. 2:49Neutron rocket it costs way more than
  68. 2:51Electron. Electron is their really
  69. 2:53really small rocket and by the way
  70. 2:55they're soon going to be launching their
  71. 2:57100th uh rocket which I think is the
  72. 3:00fastest company to to achieve that. But
  73. 3:04Neutron is very important to the
  74. 3:06long-term story of this business.
  75. 3:08Reusable rockets is very important.
  76. 3:10Capacity goes up quite a lot. More
  77. 3:12satellites go to space. The contracts
  78. 3:14get bigger and bigger. The launch
  79. 3:16contracts get of course more lucrative
  80. 3:17as well. This quarter they did tell us
  81. 3:21despite despite not launching one
  82. 3:23neutron rocket and despite many many
  83. 3:26delays we've seen total backlog
  84. 3:28increased by 52% sequentially not
  85. 3:31year-over-year sequentially to now $3.57
  86. 3:34billion. They've signed 54 launches
  87. 3:38overall worth more than a billion dollar
  88. 3:41total. They've sold eight new Neutron
  89. 3:44launches for about $515 million, which
  90. 3:48they also told us that some of them have
  91. 3:51been priced at a higher um sale price of
  92. 3:54around $70 million, which I think the
  93. 3:57base price was 15 uh $55 million. So,
  94. 4:01even with all the delays, even without
  95. 4:03launching one Neutron rocket, they
  96. 4:05managed to just increase the price to 70
  97. 4:09million. and and that's the that's the
  98. 4:11story here. The backlog is not all an
  99. 4:13option. It's sort of real contracts,
  100. 4:17but they need to deliver. There's a lot
  101. 4:19of cost going into developing a rocket
  102. 4:22such as Neutron. So hopefully hopefully
  103. 4:25a year from now we will have already had
  104. 4:28a launch of Neutron. Hopefully that
  105. 4:30backlog also keeps on increasing. We
  106. 4:32will also have the complete acquisition
  107. 4:35of Idium which would make the whole
  108. 4:37rocket lab business more profitable.
  109. 4:39Redium is already generating free cash
  110. 4:41flow. So, it helps a business that is
  111. 4:43burning cash because it is developing
  112. 4:45rockets. And who knows, maybe the first
  113. 4:47Neutron Rocket launch is going to be
  114. 4:49successful. Maybe not. But it's
  115. 4:51definitely a business that still needs a
  116. 4:53lot of cash. I do think that the big big
  117. 4:55pullback that we've experienced in the
  118. 4:58recent months does give me a big a
  119. 5:01better opportunity to accumulate more
  120. 5:03shares.
  121. 5:05>> Yeah, I think that's right. a
  122. 5:07fascinating business to watch and um
  123. 5:09incredibly wellrun as well by Sir Peter
  124. 5:12Beck. With that, I want to talk about
  125. 5:13the next stock for today. Switching
  126. 5:16gears to a completely different
  127. 5:17industry. Got to talk about healthcare.
  128. 5:19I'm going to talk about Crystal Biotech,
  129. 5:21ticker KR YS. So, Crystal Biotech, if
  130. 5:25you're not familiar, a little bit
  131. 5:26unusual in the world of growth biotech
  132. 5:28names. This is a commercial stage
  133. 5:30company. They already have an approved
  134. 5:32very profitable product. So this is not
  135. 5:34a a bet on a future clinical trial
  136. 5:36outcome. Uh Crystal Biotech's flagship
  137. 5:39drug is a therapy called VIVEC. It is
  138. 5:42the world's first topically applied
  139. 5:44atome gene therapy and it treats a
  140. 5:47condition known as uh distrophic
  141. 5:50epidermalisa or deeb. This is a very
  142. 5:52severe painful genetic skin disease. It
  143. 5:55causes horrible blistering and chronic
  144. 5:57wounds uh because of faulty collagen
  145. 5:59genes. And crystal biotech drug uses a
  146. 6:03modified a harmless version of the
  147. 6:05herpes virus to deliver a working copy
  148. 6:08of that gene right into a patient's own
  149. 6:11skin cells. So it's actually applied as
  150. 6:13a simple gel that a patient could use
  151. 6:16repeatedly at home. This isn't through a
  152. 6:18single, you know, one-time infusion. And
  153. 6:21that redossible delivery platform isn't
  154. 6:23just useful for this one rare disease.
  155. 6:25It's the foundation that Crystal Biotech
  156. 6:27is now extending to new programs where
  157. 6:30they are targeting other rare conditions
  158. 6:32of the lungs, the eyes, other rare skin
  159. 6:35disorders. So, it's really interesting,
  160. 6:38you know, how they built their platform
  161. 6:39around uh the herpes simplex virus. This
  162. 6:43is a a virus that has evolved over a
  163. 6:45long time to be good at two things,
  164. 6:46which is infecting skin cells and hiding
  165. 6:49from the body's immune system well
  166. 6:51enough to stay in a person for life
  167. 6:54without being permanently cleared. And
  168. 6:56so Crystal Biotech platform actually
  169. 6:58capitalizes on these two natural
  170. 7:00properties, but for a therapeutic
  171. 7:02purpose. Um, and that means that they
  172. 7:05are able to replace uh corrective copy
  173. 7:08of whatever gene a patient is missing,
  174. 7:11keep the virus's natural skill at
  175. 7:13slipping into skin cells without
  176. 7:14triggering any kind of a negative immune
  177. 7:16response within the patient. Now, just
  178. 7:20to put some numbers to how the company
  179. 7:22has been performing, they recently
  180. 7:24released their Q3 results in early
  181. 7:26November. Global revenue was $127
  182. 7:30million. That was up 30% year-over-year.
  183. 7:32Their cumulative revenue since they
  184. 7:34launched Fijc is now at just over a
  185. 7:37billion dollars. Uh their gross margin
  186. 7:39is at 94%. They ended the quarter with
  187. 7:42about 1.2 billion in cash and
  188. 7:45investments.
  189. 7:47Now the stock has been under a little
  190. 7:48bit of pressure uh since they reported
  191. 7:50earnings. It actually dropped around 10%
  192. 7:53or more on the day of their earnings
  193. 7:55report. And that was primarily because
  194. 7:57management disclosed that they have a
  195. 7:59few a few key clinical data readouts for
  196. 8:02two of their key pipeline candidates
  197. 8:04have been pushed into 2027 rather than
  198. 8:07being released before the end of the
  199. 8:10year. So they have a uh therapeutic
  200. 8:13candidate that targets a rare eye
  201. 8:15condition. They are going to be
  202. 8:17reporting topline results from their
  203. 8:20ongoing clinical trials early next year.
  204. 8:22They have a cystic fibrosis therapy that
  205. 8:25has now uh been delayed the results
  206. 8:28until the first half of 2027. Says
  207. 8:31nothing about uh you know anything with
  208. 8:33regards to the business to be concerned
  209. 8:34about but just something to be aware of.
  210. 8:37You know Crystal Biotech has continued
  211. 8:38to expand internationally. They have uh
  212. 8:41of course expanded and launched within
  213. 8:43the US but they are done with pricing
  214. 8:45and reimbursement negotiations in
  215. 8:47markets like Germany and Italy. So,
  216. 8:49they're going to be launching uh within
  217. 8:51some of these markets as early as the
  218. 8:53beginning of 2027. Uh they're already
  219. 8:56benefiting from earlier European
  220. 8:58launches as well as expansion in Japan.
  221. 9:02And I'll also note that Crystal Biotech
  222. 9:04Board has authorized a $400 million
  223. 9:06share buyback program that's going to be
  224. 9:08executed over the next couple years. So,
  225. 9:11fascinating business, very much in the
  226. 9:13early stages of its growth. It has its
  227. 9:15one very profitable key flagship
  228. 9:17product, but they are rapidly expanding
  229. 9:19into other rare disease areas. It's a
  230. 9:22profitable business. It's a high margin
  231. 9:23one. Might be one to at least put on
  232. 9:26your watch list, if not your buy list,
  233. 9:28if you're interested in putting cash to
  234. 9:30work in biotech stocks.
  235. 9:33>> Very interesting name. I mean, the
  236. 9:34biotech
  237. 9:36segment of the market is one where it's
  238. 9:39either you're going to be very very
  239. 9:40successful or or it's a name where you
  240. 9:43probably won't hear about it a couple of
  241. 9:46years a couple of years down the line,
  242. 9:47but from what I I've just heard and and
  243. 9:50seen seems like a a pretty good company
  244. 9:52has also performed quite well uh this
  245. 9:54year and and over the past uh 12 months.
  246. 9:57So, pretty pretty good. Um my my next
  247. 10:00one is is a company that well how should
  248. 10:04I say over the last couple of years has
  249. 10:06completely changed changed the game in
  250. 10:09the in the stock market over the past
  251. 10:11couple of days has definitely changed
  252. 10:14something in uh in the news market and
  253. 10:17that's Nvidia. Now Nvidia we all know it
  254. 10:21I mean now it's not a $5 trillion
  255. 10:23company anymore. it has lost a little
  256. 10:25bit of it of its market cap over the
  257. 10:27past couple of days and weeks.
  258. 10:31Some of the reasons we know what's going
  259. 10:32on in the headlines right now with uh
  260. 10:35with the CEO, but I do want to talk
  261. 10:36about the business itself because the
  262. 10:39business is still a tremendous business.
  263. 10:42Yes, it's true that Jensen being the
  264. 10:45CEO, Jensen being Nvidia, Nvidia being
  265. 10:47Jensen, if let's say he were to step
  266. 10:50down, that could cause some pressure on
  267. 10:52the stock, would it would it be a thesis
  268. 10:56changer? I I doubt it because I do think
  269. 10:59that Nvidia has become a such a big
  270. 11:02company that that could be run by
  271. 11:05someone else. Of course, ideally Jensen
  272. 11:08does stay the company, but purely
  273. 11:09looking at the business today. I don't
  274. 11:12think that anything will change anytime
  275. 11:14soon. I still think they'll grow at
  276. 11:16least 70% uh next year. I still think
  277. 11:19that Google, Amazon, OpenAI, all of
  278. 11:22these uh companies are still going to
  279. 11:24buy Nvidia GPUs for for the foreseeable
  280. 11:27future. and and that represents right
  281. 11:30now a a a in my opinion a buying
  282. 11:33opportunity because valuation wise I
  283. 11:35think we're at 17 times forward earnings
  284. 11:38or or close to it of course generating
  285. 11:41an insane amount of free cash flow over
  286. 11:43the next couple of years will be
  287. 11:44generating well over half a trillion
  288. 11:46dollars in in free cash flow which is
  289. 11:49which is mindboggling so despite all of
  290. 11:52the headlines more recently whether it's
  291. 11:55around uh data center buildout AI high
  292. 11:58investments or now the new headlines
  293. 12:00that have popped up uh the the
  294. 12:02controversy around around the the CEO. I
  295. 12:06do think that the pressure of the stock
  296. 12:08does present long-term investors a a
  297. 12:11nice opportunity where the riskreward
  298. 12:13definitely favors the rewards or at
  299. 12:15least for me again because I do think
  300. 12:18that the AI buildout does continue. We
  301. 12:21spoke about cororewe in a in a previous
  302. 12:24video. Of course, Nvidia is an investor
  303. 12:26in Cororeef. Corre does buy a lot of
  304. 12:28Nvidia chips. Yes, we could say that
  305. 12:30Nvidia also backs Cororey, although two
  306. 12:33different terms maybe, but uh if
  307. 12:35Cororeef doesn't manage to to to sell X
  308. 12:38amount of chips, Nvidia will come in and
  309. 12:41and back them for at least I think $6
  310. 12:43billion or so. Some might like these
  311. 12:45deals, some might not. That's completely
  312. 12:47fine. But
  313. 12:50Nvidia is is in a very good spot at the
  314. 12:53moment in this whole AI buildout. Stock
  315. 12:56is cheap. Business is growing. I mean
  316. 12:58the size of the business. This is now a
  317. 13:00four plus trillion dollar company
  318. 13:02generating tens of billions, hundreds of
  319. 13:04billions of dollars in revenue while
  320. 13:06still growing at least 70%. That's for
  321. 13:09next year. This year is going to be
  322. 13:10closer to 90% or so. very very
  323. 13:13profitable despite despite some of their
  324. 13:15biggest customers also becoming let's
  325. 13:18say rivals
  326. 13:20all designing their own custom silicon
  327. 13:23or the old custom chips working with
  328. 13:25Broadcom working with Marvel so yes
  329. 13:28there is a lot of com or AMD as well uh
  330. 13:30we've seen the Google TPU's uh
  331. 13:32announcement with uh with AMD I think on
  332. 13:34Monday so competition is increasing I do
  333. 13:38also think the momentum the market is
  334. 13:40just growing so much Nvidia's position
  335. 13:42very well very profitable company. Yes,
  336. 13:46unfortunately we do have some negative
  337. 13:48headlines affecting the stock. Could it
  338. 13:51affect the business? There's definitely
  339. 13:53a chance that it could affect the
  340. 13:55business where XYZ were to happen over
  341. 13:58the next couple of weeks. So, we'll see.
  342. 14:01But purely looking at valuation and
  343. 14:04business performance, I'd had to put uh
  344. 14:07this name right now on the list,
  345. 14:09especially since we are at the end of
  346. 14:112026 and I didn't think we would see an
  347. 14:12Nvidia trading at 17 times forward
  348. 14:15earnings by the end of this year.
  349. 14:18Yeah, I mean certainly the financial
  350. 14:20foundation of Nvidia, the business is
  351. 14:24you know running like a welloiled
  352. 14:25machine and the tailwinds that are
  353. 14:27driving the business forward just
  354. 14:29broadly those secular tailwinds are not
  355. 14:31going to go anywhere regardless of what
  356. 14:33happens with you know the story that
  357. 14:36we're seeing around the CEO in the
  358. 14:38coming weeks and months. Who knows if we
  359. 14:40will see a leadership change or not, but
  360. 14:43uh and that may in fact be you know
  361. 14:45necessary and that may shake the stock
  362. 14:46up and you know we will see. We don't
  363. 14:48want to speculate about what's going to
  364. 14:50happen. Um but certainly the core
  365. 14:52underlying business uh is one that I
  366. 14:55think remains deeply tethered to the AI
  367. 14:58buildout that's arguably one of the most
  368. 14:59recognizable names in the space. Um and
  369. 15:02probably has one of the strongest
  370. 15:03financial foundations of any of the AI
  371. 15:05companies uh that we talk about. Um, for
  372. 15:08the final stock in today's video, I'm
  373. 15:10going to talk about another healthcare
  374. 15:11name. Another one that's probably a bit
  375. 15:13less known. Trying to shake it up a
  376. 15:15little bit. You know, we see in the
  377. 15:16comments sometimes that you guys uh
  378. 15:18mention that we only talk about tech
  379. 15:19stocks. So, I'm trying to shake things
  380. 15:21up a bit. We'll see. Uh, so Billionto
  381. 15:23One, uh, ticker B LLN. If you're not
  382. 15:26familiar with Billion to One, this is
  383. 15:28certainly not a household name. They are
  384. 15:30a molecular diagnostics company. So
  385. 15:32their platform is built around a kind of
  386. 15:34proprietary technology that it calls
  387. 15:37quantitating quantitative counting
  388. 15:39templates or QCT. This is essentially a
  389. 15:42platform that can detect and measure uh
  390. 15:44genetic material with a level of
  391. 15:46sensitivity that the legacy diagnostic
  392. 15:49companies generally can't match. And
  393. 15:51Billionto one applies that technology
  394. 15:53across a couple different product lines.
  395. 15:56The first and currently its flagship
  396. 15:58business is prenatal testing. uh they
  397. 16:01have the first and only non-invasive
  398. 16:03prenatal tests uh for red blood cell and
  399. 16:06platelet fetal antigens in the US. The
  400. 16:08second is their oncology business and
  401. 16:10they are currently building out a an
  402. 16:12entire family of liquid biopsy tests
  403. 16:15that can detect and monitor cancer from
  404. 16:17a simple blood draw rather than
  405. 16:19requiring an invasive tissue biopsy. And
  406. 16:21the oncology business is the one that
  407. 16:23I'm most excited about that I think will
  408. 16:25be most important to the business and
  409. 16:27its growth story moving forward.
  410. 16:30So one of the things that's interesting
  411. 16:32uh talking about the the platform
  412. 16:34technology that billion to one runs on
  413. 16:38um just to explain why it's a bit more
  414. 16:41differentiated. So when you draw blood
  415. 16:43from a pregnant woman there's a t tiny
  416. 16:45amount of fetal DNA that's floating
  417. 16:47freely in her bloodstream and that's
  418. 16:49mixed in with a much larger amount of
  419. 16:51her DNA. So pulling a faint specific
  420. 16:53fetal signal out of that much larger
  421. 16:55background of DNA is sort of the central
  422. 16:58challenge of non-invasive prenatal
  423. 17:00testing. That same kind of basic core
  424. 17:03challenge also shows up in cancer
  425. 17:05testing. So for example, after a tumor
  426. 17:07is removed, there might only be a
  427. 17:09handful of cancer DNA fragments floating
  428. 17:11among millions of healthy ones. And so
  429. 17:13finding those few fragments is what
  430. 17:15minimal residual disease testing is
  431. 17:18actually trying to do. billion to one's
  432. 17:20platform attaches a unique tag to each
  433. 17:25individual DNA molecule. So they can
  434. 17:27actually count those molecules rather
  435. 17:29than estimate their proportion. You
  436. 17:31could sort of think of it of as the
  437. 17:33difference between weighing a mixed bag
  438. 17:35of coins to estimate how many quarters
  439. 17:36are in it versus tagging and counting
  440. 17:38each coin at a time. And that precision,
  441. 17:41that single molecule level precision is
  442. 17:43what allows billion to one to offer
  443. 17:46these very accurate diagnostic tests
  444. 17:49that so far some of the more established
  445. 17:50competitors have not. Um, and this is
  446. 17:53showing up in the numbers as well. So
  447. 17:55they reported also about a week ago
  448. 17:57their third quarter results. Total
  449. 17:59revenue
  450. 18:00uh beat uh consensus estimates was up
  451. 18:04about 50% year-over-year. saluted
  452. 18:06earnings per share was more than double
  453. 18:08what Wall Street was expecting. Their
  454. 18:10prenatal revenue was up 41%
  455. 18:12year-over-year. Their oncology revenue,
  456. 18:14which is still a smaller, but the
  457. 18:15fastest growing part of the business,
  458. 18:17was up 96% year-over-year, is now
  459. 18:20running at an annualized rate of about
  460. 18:2168 million. They generated about $9
  461. 18:24million in free cash flow in the
  462. 18:26quarter. It was their fifth consecutive
  463. 18:28quarter of positive GAP operating
  464. 18:31income. They have about 562 million in
  465. 18:34cash and cash equivalents on their
  466. 18:35balance sheet. One of the biggest things
  467. 18:37to watch as it pertains to the oncology
  468. 18:39business, they have a new test that they
  469. 18:42are launching in mid December. This is a
  470. 18:44a test for minimal residual disease.
  471. 18:46Basically, it's designed to detect the
  472. 18:48microscopic traces of cancer left behind
  473. 18:50after a patient's tumor has already been
  474. 18:53surgically removed. It's a blood only
  475. 18:55test. It is available for all solid
  476. 18:57tumors. Was day one. um and they're
  477. 18:59going to be uh launching this again here
  478. 19:02in the next few weeks. And so this is uh
  479. 19:05key as they are growing out their cohort
  480. 19:07of oncology tests. It it's a fascinating
  481. 19:10business. It's a profitable one. It's
  482. 19:13one that's continuing to see really
  483. 19:14solid growth across both their prenatal
  484. 19:17natal testing and oncology businesses.
  485. 19:20Uh but to me the fact that they are
  486. 19:22launching these really differentiated
  487. 19:24cancer monitoring products into uh a
  488. 19:27vast addressable market management uh
  489. 19:30estimates that that market is worth
  490. 19:31about $30 billion on top of this already
  491. 19:34validated technology platform. I think
  492. 19:37there's a long way for billion to want u
  493. 19:40to run and I think this is certainly a
  494. 19:41business to at least put on your watch
  495. 19:43list before the end of 2026.
  496. 19:46It's certainly a very cool name.
  497. 19:49>> Billion to one. It's very catchy.
  498. 19:52>> Yeah.
  499. 19:53>> Okay, everyone. That's [music] four
  500. 19:54stocks that Neil and I would consider
  501. 19:56buying before the end of 2026. For Neil,
  502. 19:59we [music] had Rocket Lab and Nvidia. I
  503. 20:01talked about two healthcare names,
  504. 20:02Crystal Biotech and Billion. [music] Let
  505. 20:05us know your thoughts in the comments.
  506. 20:06What stocks are on your buy lists before
  507. 20:09the end of the year? Let us know. Hit
  508. 20:11the like and subscribe buttons and we
  509. 20:13will see you in the next video.

About this transcript

This page contains the full transcript of 4 Stocks to Buy Before the End of 2026! by The Motley Fool, generated from the public captions YouTube serves with the video. The transcript has 3,408 words across 509 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.